ACST Insider Trading

Insider Ownership Percentage: 13.51%
Insider Buying (Last 12 Months): $1,252,067.40
Insider Selling (Last 12 Months): $0.00

Acasti Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Acasti Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acasti Pharma Share Price & Price History

Current Price: $2.84
Price Change: Price Decrease of -0.11 (-3.73%)
As of 07/19/2024 09:55 PM ET

This chart shows the closing price history over time for ACST up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Acasti Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2023Vimal KavuruDirectorBuy676,371$1.85$1,251,286.351,188,076View SEC Filing Icon  
8/31/2023Donald OldsDirectorBuy381$2.05$781.05381View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Acasti Pharma (NASDAQ:ACST)

6.08% of Acasti Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ACST by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Acasti Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2021Two Sigma Securities LLC13,370$27K0.0%N/A0.051%Search for SEC Filing on Google Icon
11/12/2021Edmond DE Rothschild Holding S.A.12,500$25K0.0%-87.5%0.048%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC732,222$0.41M0.0%-19.9%2.811%Search for SEC Filing on Google Icon
8/16/2021Squarepoint Ops LLC94,500$53K0.0%+392.4%0.045%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC1,744,236$0.98M0.0%N/A0.837%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC146,784$82K0.0%-15.9%0.070%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC913,651$0.55M0.0%+32.8%0.438%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC100,617$60K0.0%N/A0.048%Search for SEC Filing on Google Icon
5/17/2021Edmond DE Rothschild Holding S.A.100,000$60K0.0%N/A0.048%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC687,985$0.22M0.0%+412.3%0.710%Search for SEC Filing on Google Icon
2/11/2021Oppenheimer & Co. Inc.224,965$73K0.0%+15.5%0.232%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC1,924,000$0.63M0.0%N/A1.986%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC134,296$27K0.0%-46.8%0.139%Search for SEC Filing on Google Icon
8/7/2020Virtu Financial LLC252,405$0.12M0.0%N/A0.276%Search for SEC Filing on Google Icon
5/15/2020Morgan Stanley160,785$61K0.0%-9.9%0.178%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Acasti Pharma logo
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Read More on Acasti Pharma

Today's Range

Now: $2.84
Low: $2.84
High: $3.03

50 Day Range

MA: $2.96
Low: $2.60
High: $3.30

52 Week Range

Now: $2.84
Low: $1.72
High: $3.59

Volume

11,400 shs

Average Volume

20,961 shs

Market Capitalization

$26.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Who are the company insiders with the largest holdings of Acasti Pharma?

Acasti Pharma's top insider shareholders include:
  1. Vimal Kavuru (Director)
  2. Donald Olds (Director)
Learn More about top insider investors at Acasti Pharma.